Cutaneous Corticosteroid Therapy and Cataract in Man

Branco, Nara; Branco, Bruno Castelo; Maibach, Howard I.

doi:10.1081/cus-120013036

Cited by 8 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glaucoma is a reported finding known to be associated with steroid use but the incidence is not well defined. Similarly, while an association between systemic use of steroids and posterior subcapsular cataract has been extensively documented, an analysis of the literature from 1996 to 2001 yielded only seven cases in patients receiving TS 37 . Thus, there is a possible, but unsubstantiated, risk of cataracts associated with the use of TS.…”

Section: Resultsmentioning

confidence: 99%

A systematic review of the safety of topical therapies for atopic dermatitis

et al. 2007

View full text Add to dashboard Cite

Summary Background The safety of topical therapies for atopic dermatitis (AD), a common and morbid disease, has recently been the focus of increased scrutiny, adding confusion as how best to manage these patients. Objectives The objective of these systematic reviews was to determine the safety of topical therapies for AD. Methods Databases searched included: OVID Medline, Medline In‐Process and Other Non‐Indexed Citations, Embase, and the Cochrane Central Register of Controlled Trials. In addition to the articles identified by this search, investigators were also referred to a list of links (most recently updated 25 September 2005) to recent Food and Drug Administration (FDA) studies, reports and meetings regarding the topical calcineurin inhibitors for further potential references. Only fully published papers available in English and data obtained from FDA sites were included. Furthermore, the criteria for inclusion and exclusion for each systematic review were further evaluated at a meeting of all of the content and evidence‐based medicine experts participating in this process and alteration of the inclusion criteria was done at that time when it was felt necessary to avoid inclusion of lower‐quality data in the review. Qualitative review of the abstracted data was performed and reviewed at a meeting of all of the content and evidence‐based medicine experts. Results While systemic exposure to these topical agents does occur, physiological changes appear to be uncommon and systemic complications rare and have only been found with use of topical corticosteroids. Conclusions Based on the data that are available the overall safety of AD therapies appears to be good with the only documented systemic side‐effects of therapy those occasionally seen with use of topical corticosteroids.

show abstract

Section: Resultsmentioning

confidence: 99%

A systematic review of the safety of topical therapies for atopic dermatitis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…76 Lower doses of systemic corticosteroids in combination with TCS use in the periocular region, subconjunctival and nasal steroid sprays has also been associated with posterior subcapsular cataracts, with seven cases reported in a 5-year period to 2001. 77 In a study of 37 atopic eczema patients who used moderate potency TCS periorbitally for an average of 6 months/ year over 5 years, seven were found to have cataracts. 72 Two of these patients were also using oral steroids, four of the seven were found to have age-related cataracts and one patient was found to have cataracts secondary to rubbing, in the setting of atopic eczema.…”

Section: Ocular Effectsmentioning

confidence: 99%

Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement

et al. 2015

View full text Add to dashboard Cite

Atopic eczema is a chronic inflammatory disease affecting about 30% of Australian and New Zealand children. Severe eczema costs over AUD 6000/year per child in direct medical, hospital and treatment costs as well as time off work for caregivers and untold distress for the family unit. In addition, it has a negative impact on a child's sleep, education, development and self-esteem. The treatment of atopic eczema is complex and multifaceted but a core component of therapy is to manage the inflammation with topical corticosteroids (TCS). Despite this, TCS are often underutilised by many parents due to corticosteroid phobia and unfounded concerns about their adverse effects. This has led to extended and unnecessary exacerbations of eczema for children. Contrary to popular perceptions, (TCS) use in paediatric eczema does not cause atrophy, hypopigmentation, hypertrichosis, osteoporosis, purpura or telangiectasia when used appropriately as per guidelines. In rare cases, prolonged and excessive use of potent TCS has contributed to striae, short-term hypothalamic-pituitary-adrenal axis alteration and ophthalmological disease. TCS use can also exacerbate periorificial rosacea. TCS are very effective treatments for eczema. When they are used to treat active eczema and stopped once the active inflammation has resolved, adverse effects are minimal. TCS should be the cornerstone treatment of atopic eczema in children.

show abstract

The Skin and the Eyes

Leonard¹,

Dart²

2004

Rook's Textbook of Dermatology

View full text Add to dashboard Cite

Cutaneous Corticosteroid Therapy and Cataract in Man

Cited by 8 publications

References 29 publications

A systematic review of the safety of topical therapies for atopic dermatitis

A systematic review of the safety of topical therapies for atopic dermatitis

Adverse effects of topical corticosteroids in paediatric eczema: Australasian consensus statement

The Skin and the Eyes

Contact Info

Product

Resources

About